

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

 ATTY. DOCKET NO.
4518-0107PUS1

APPLICATION NO.

10/519323

APPLICANT

LOIBNER, Hans et al.

FILING DATE

December 23, 2004

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
/M.N./	EP	0528767	A	1993-02-24	EUROPE				
/M.N./	WO	0100245	A	2001-01-04	WO				
/M.N./	WO	02092771	A	2002-11-21	WO				
/M.N./	WO	0170268	A1	2001-09-21	WO	✓			
/M.N./	WO	8911288	A1	1989-11-30	WO	✓			
/M.N./	WO	0233073	A1	2002-04-25	WO	✓			X

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

/M.N./	DETTKE, M. et al.: "Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro" British Journal of Cancer, Vol. 82, No. 2, January 2000, pp. 441-445
/M.N./	BASU, A. et al.: "Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas" Cancer Research, Vol. 47, No. 10, 15 May 1987, pp. 2531-2536
/M.N./	GOOI, H.C. et al: "Monoclonal antibody (EGR/G49) reactive with the epidermal growth factor receptor of A431 cells recognizes the blood group ALeb and ALeY structures" Molecular Immunology, Vol. 22, No. 6, June 1985, pp. 689-693
/M.N./	BRICH, Z, et al: "Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364)" Journal of Controlled Release, Vol. 19, No. 1/3, 1 March 1992, pp. 245-257.

EXAMINER

/Meera Natarajan/

DATE CONSIDERED

09/11/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.